Business
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that four posters in Rett syndrome will be presented at the upcoming
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that four posters in Rett syndrome will be presented at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Mass.\n\n\nThe poster presentations include a secondary analysis reporting on the communication-related endpoints from the pivotal Phase 3 LAVENDER™ study and an interim analysis of the ongoing, open-label DAFFODIL™ study. Additional poster presentations include physician survey data to illustrate the current state of Rett syndrome treatment and healthcare resource utilization in children with Rett syndrome.\n\n\nAAN Accepted Posters:\n\n\n\nP12 - Poster Session 12/P12.4-002: Clinical Management of Rett Syndrome in the Real World: A Physician Survey. Online and in person, Wednesday, April 26, 5:30 – 6:30 p.m. ET\n\n\n\nP13 - Poster Session 13/P.13.9-004: Elevated Healthcare Resources Utilization and Costs Among Individuals Diagnosed with Rett Syndrome. Online and in person, Thursday, April 27, 8:00 – 9:00 a.m. ET\n\n\n\nP13 - Poster Session 13/P13.9-005: Trofinetide for the Treatment of Rett Syndrome: An Open-Label Study in Girls Aged 2 to 4 Years. Online and in person, Thursday, April 27, 8:00 – 9:00 a.m. ET\n\n\n\nP13 - Poster Session 13/P13.9-006: Treatment with Trofinetide Shows Benefit Compared with Placebo in the Ability to Communicate in Individuals with Rett syndrome. Online and in person, Thursday, April 27, 8:00 – 9:00 a.m. ET\n\n\n\nAbout Rett Syndrome\n\n\nRett syndrome is a rare, complex, neurodevelopmental disorder that may occur over four stages and affects approximately 6,000 to 9,000 patients in the U.S., with approximately 4,500 patients currently diagnosed according to an analysis of healthcare claims data.1-4 A child with Rett syndrome exhibits an early period of apparently normal development until six to 18 months, when their skills seem to slow down or stagnate. This is typically followed by a duration of regression when the child loses acquired communication skills and purposeful hand use. The child may then experience a plateau period in which they show mild recovery in cognitive interests, but body movements remain severely diminished. As they age, those living with Rett may continue to experience a stage of motor deterioration which can last the rest of t...